HistoneH3 (1-35) is a 35-residue peptide derived from histoneH3, which is a key member of the five main histones participating in the formation of chromatin within eukaryotic cells.
HistoneH3 (21-44), derived from a sequence of 21-44 amino acids of histoneH3, is commonly employed as a substrate, particularly for protein arginine methyltransferase assays, where methylation activity is being examined.
HistoneH3 (23-34) is a peptide consisting of amino acid residues 23 to 34 of the histoneH3 protein. This peptide specifically includes lysine residues at positions 23 and 27, which can undergo methylation and acetylation modifications.
HistoneH3 (1-21) is a truncated form of the HistoneH3 protein consisting of amino acids 1 to 21. It serves as a common substrate for methyltransferase assays targeting Histone 3 at lysine 4 and lysine 9, as well as for acetyltransferase assays targeting Histone 3 at lysine 9 and lysine 14.
HistoneH3 (21-44)-GK-biotin is a peptide fragment of histoneH3 that corresponds to amino acid residues 22-45 of the human histoneH3.1 and 3.2 sequences and is biotinylated via a C-terminal GK linker. HistoneH3 (21-44) contains a lysine residue at position 23 that is subject to acetylation, an arginine at position 26 subject to methylation, and a serine at position 28 subject to phosphorylation, as well as lysine residues at positions 27 and 36 that are subject to methylation and acetylation. HistoneH3 (21-44)-GK-biotin has been used as a substrate for the primate-specific histone methyltransferase PR domain-containing protein 7 (PRDM7) to determine substrate specificity.
HistoneH3 (21-44)-GK-biotin is a peptide fragment of histoneH3 that corresponds to amino acid residues 22-45 of the human histoneH3.3 sequence and is biotinylated via a C-terminal GK linker. Unlike histoneH3.1 and H3.2, the histoneH3.3 variant contains a serine residue at position 31 that is phosphorylated during late prometaphase and metaphase of mitosis. HistoneH3 (21-44) also contains lysine residues at positions 23, 27, and 36 that are subject to methylation and acetylation, all of which have a role in the regulation of gene expression, and a serine residue at position 28 that is subject to phosphorylation during mitosis.
HistoneH3 (1-25), amide is a N-terminal peptide fragment of histoneH3 that serves as a substrate for histone methyltransferases (HMTs). It can be utilized to identify the substrate for HMTs. Compared to histoneH3 (15-39) and full-length histoneH3, HistoneH3 (1-25), amide proves to be more efficient as a substrate for HMT G9a.
HistoneH3K27Me1 (23-34) is a peptide fragment of histoneH3 that corresponds to amino acid residues 24-35 of the human histoneH3.1 and H3.2 sequences. Monomethylation of histoneH3 at lysine 27 is associated with actively transcribed genes and positively correlates with H3K36 trimethylation. Levels of H3K27Me1 are increased in tumor tissue isolated from patients with metastatic hormone-na ve and castration-resistant prostate cancer. HistoneH3K27Me1 (23-34) has been used in epitope mapping of the lupus-derived monoclonal antibody BT164.
LSD1-IN-5 increases dimethylated Lys4 of histoneH3, shows no effect on expression of LSD1. LSD1-IN-5 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM.
LSD1-IN-6 increases dimethylated Lys4 of histoneH3, shows no effect on expression of LSD1. LSD1-IN-6 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM.